Treatment with either SEED-BT or RP had comparable oncological outcomes for patients with intermediate-risk prostate cancer for our median 8-year follow-up even when the BCR rate was calculated using the same definition of a PSA cut-off value of 0.2 ng/mL for both treatments. The gene discussed is KLK3; the disease is prostate carcinoma.